Clinical trials: Patients with Advanced Solid Tumors
Solid Tumor
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.
- Trial name
- NCT04346381
- Testing
- Camrelizumab, Famitinib
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neoplasms
A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
This study will evaluate safety and tolerability to estimate the MTDand/or recommended dose.
- Trial name
- NCT01911936
- Testing
- LM716
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Advanced/Metastatic Solid Tumors
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
Phase I/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors This study is a first-in-human phase I/II, multicenter, open-label, dose-escalation trial with PK expansion and cohort expansion, designed…
- Trial name
- NCT07415863
- Testing
- SYS6043
- Where
- China
- Volunteers
- 820 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Solid Tumor Malignancies
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
This study employs a single-arm, open-label, non-randomized, dose-escalation design to investigate the safety, tolerability, and efficacy of GO306 Recombinant Oncolytic Vaccinia Virus Injection.
- Trial name
- NCT07128914
- Testing
- GO306
- Where
- 6 sites in China
- Volunteers
- 32 people
- Sponsor
- GeneSail Biotech (Shanghai) Co., Ltd.
Solid Tumor, Lymphoma
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.
- Trial name
- NCT05357651
- Testing
- LB1410
- Where
- China
- Volunteers
- 100 people
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China
Advanced Malignant Solid Tumor
PRL3-Zumab in Patients With Advanced Solid Tumors
This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors.
- Trial name
- China Phase II (NCT07541001)
- Testing
- PRL3-ZUMAB
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Neoplasms
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of [177Lu]-NeoB in patients with advanced solid tumors known to overexpress…
- Trial name
- NeoRay (NCT03872778)
- Testing
- [177Lu]-NeoB, [68Ga]-NeoB, LCZ696
- Where
- 11 sites in United States, Austria and 4 more
- Volunteers
- 35 people
- Sponsor
- Advanced Accelerator Applications
Solid Tumors
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
The goal of this study is to determine the dose of LY573636-sodium (hereafter referred to as LY573636) that can be administered safely in combination with liposomal doxorubicin in patients with advanced cancer who have failed a…
- Trial name
- NCT01214668
- Testing
- LY573636-sodium, Liposomal Doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Cancer
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients
- Trial name
- NCT00562913
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 2 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Bayer
Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild, moderate, or severe hepatic impairment.
- Trial name
- NCT01991678
- Testing
- 145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nektar Therapeutics
Advanced/Metastatic Solid Tumors, Colorectal Cancer
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC.
- Conditions
- Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT03526835
- Testing
- MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI
- Where
- 54 sites in United States, Belgium and 5 more
- Volunteers
- 560 people
- Sponsor
- Genmab
Solid Tumor, Adult
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
The Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced…
- Trial name
- GDFATHER (NCT04725474)
- Testing
- visugromab (CTL-002), nivolumab
- Where
- 13 sites in Germany, Spain and 1 more
- Volunteers
- 199 people
- Sponsor
- CatalYm GmbH
Solid Tumor, Adult
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
A mutilpe-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX55 in patients with advanced solid tumors overexpressing/Mutation/Amplification cMET after failure of standard…
- Trial name
- NCT04169178
- Testing
- HLX55
- Where
- 4 sites in Taiwan
- Volunteers
- 98 people
- Sponsor
- Henlix, Inc
Advanced Solid Tumors
AMT-562 in Patients With Selected Advanced Solid Tumors
This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study of AMT-562 in patients with advanced solid tumors.
- Trial name
- NCT06199908
- Testing
- AMT-562
- Where
- 2 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Multitude Therapeutics (Australia) Pty Ltd
Solid Tumors, Head and Neck Cancer
A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer
This is an open-label, multicenter, dose-escalation phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of SYH2051 in patients with advanced solid tumors or in combination with…
- Trial name
- NCT06011291
- Testing
- SYH2051 tablets, Intensity-Modulated Radiation Therapy (IMRT)
- Where
- China
- Volunteers
- 73 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Advanced Solid Tumour
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
- Trial name
- NCT07331155
- Testing
- LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Tumor, Tumor, Solid
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
- Trial name
- NCT05103358
- Testing
- nab-sirolimus
- Where
- 166 sites in United States, Puerto Rico and 1 more
- Volunteers
- 128 people
- Sponsor
- Aadi Bioscience, Inc.
Neoplasms
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid…
- Trial name
- NCT01022853
- Testing
- BI 6727, BIBF 1120
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, preliminary efficacy and pharmacokinetics of Simmitecan in patients with advanced solid tumors and Simmitecan, 5-fluorouracil and Leucovorin Calcium,thalidomide in patients with…
- Trial name
- NCT02870036
- Testing
- Simmitecan, 5-fluorouracil and Leucovorin Calcium, Thalidomide
- Where
- 9 sites in China
- Volunteers
- 243 people
- Sponsor
- Haihe Biopharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.